Latest Insider Positions

DREES SCOTT F is listed as an insider in the following companies: NVTR / Nuvectra Corporation Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.


Security Title Post Shares
NVTR / Nuvectra CEO, Director 205,320

Latest Transactions

Tran Date
Security Code Shares Post Shares Percent
2018-10-07 NVTR / Nuvectra M 16,024 205,320 8.47 24.32 389,704
2018-07-07 NVTR / Nuvectra M 16,024 189,296 9.25 18.09 289,874
2018-04-07 NVTR / Nuvectra M 16,024 173,272 10.19 13.05 209,113
2018-01-07 NVTR / Nuvectra M 16,024 157,248 11.35 7.86 125,949
2017-10-07 NVTR / Nuvectra M 16,044 141,224 12.82 13.44 215,631
2017-08-11 NVTR / Nuvectra P 10,000 125,180 8.68 11.72 117,200 1,467,110 7.99
2017-07-07 NVTR / Nuvectra M 16,044 115,180 16.18 13 208,572
2017-05-30 NVTR / Nuvectra P 7,395 99,136 8.06 10.41 76,982 1,032,006 7.46
2017-05-25 NVTR / Nuvectra P 1,700 91,741 1.89 9.95 16,915 912,823 1.85
2017-05-24 NVTR / Nuvectra P 905 90,041 1.02 9.85 8,914 886,904 1.01
2017-04-07 NVTR / Nuvectra M 64,136 89,136 256.54 6.36 407,905
2017-03-14 NVTR / Nuvectra P 17,100 25,000 216.46 6.19 105,849 154,750 68.40
2017-03-13 NVTR / Nuvectra P 7,900 7,900 31.60 6.25 49,375 49,375 100.00
2016-04-08 NVTR / Nuvectra A 192,368 192,368
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)

Peers of DREES SCOTT F include the following: BERGER WALTER Z, Bihl Anthony P III, Fahey Kathy Jo, GREATBATCH, INC., HAWARI KENNETH G, Hanchin Joseph Paul, Hickman Thomas Kelley, JOHNSON DAVID D, Kaula Norbert, Kosharek Jennifer, MILLER JOSEPH A, PARKS FRED B, Tranchina Benjamin, Tremmel Jon T, Zelibor Thomas Edward, . Peers are determined by cross-linking the filings of DREES SCOTT F with insider filings of others at the same companies.

Related News Stories

Implied Volatility Surging for Nuvectra (NVTR) Stock Options

2018-09-24 zacks
Investors in Nuvectra Corporation (NVTR - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 16, 2018 $20.00 Call had some of the highest implied volatility of all equity options today.

Are Options Traders Betting on a Big Move in Nuvectra (NVTR) Stock?

2018-08-21 zacks
Investors in Nuvectra Corporation (NVTR - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $17.50 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.

Nuvectra Corporation (NVTR) CEO Scott Drees on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
Good day, ladies and gentlemen, and welcome to the Q2 2018 Nuvectra Earnings Conference Call. [Operator Instructions] As a reminder, this conference call may be recorded. (3-0)

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

2018-07-03 seekingalpha
RedHill Biopharma (RDHL) announced that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The patents will be in effect until 2029. The company has an important upcoming catalyst related to its RHB-104 candidate. Topline Phase 3 data of RHB-104 trial MAP-US on Crohn's disease expected in early August 2018. (27-2)

Why Nuvectra Is Monday’s Big Biotech Loser

2018-07-02 247wallst
Nuvectra Corp. (NASDAQ: NVTR) shares were crushed on Monday after the company announced an update on its U.S. Food and Drug Administration (FDA) premarket approval (PMA) application and its TÜV SÜD application for CE Mark in Europe for Virtis. (1-0)